Printer Friendly

Precision Therapeutics secures rights to novel technology from GLG Pharma.

Precision Therapeutics said it has acquired rights to technology for the proprietary culture media to grow ovarian cancer cell types in the laboratory for research and testing. Precision's joint venture partner, GLG Pharma LLC, has agreed to terms on a non-exclusive license to this technology from a research institution. TumorGenesis, a wholly owned subsidiary of Precision, has developed a discovery kit using this technology for screening of these ovarian cancer cell types. This effort is part of the partnership of TumorGenesis and GLG to advance ovarian cell capture, culture and chemistry. 14 of the 24 identified ovarian cancer cell types represent nearly 90% of all ovarian cancers, TumorGenesis' first drug discovery target. The development of the kit is the first milestone in the company's quest to grow human tumors outside the body. The next three milestones include identifying the peptides and structure needed to grow a tumor, selecting the one that works the best, and then growing a tumor exogenously.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Nov 7, 2018
Previous Article:MiMedx adopts limited duration shareholder rights plan after Nasdaq delisting.
Next Article:Newell Brands to sell Pure Fishing, Jostens for proceeds of approx. $2.5B.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters